Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker GNLX
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 3, 2026 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 668 | $2.04 | $1,363 Sale | Form 4 ↗ |
| Nov 3, 2026 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 3,089 | $2.05 | $6,317 Sale | Form 4 ↗ |
| Nov 3, 2026 | Yong Yu Chief Scientific Officer | GNLX Genelux Corporation | Sale | 668 | $2.01 | $1,344 Sale | Form 4 ↗ |
| Aug 31, 2026 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 10,257 | $2.74 | $28.1K Sale | Form 4 ↗ |
| Aug 31, 2026 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 34,463 | $2.67 | $92.0K Sale | Form 4 ↗ |
| Aug 31, 2026 | Yong Yu Chief Scientific Officer | GNLX Genelux Corporation | Sale | 9,683 | $2.75 | $26.6K Sale | Form 4 ↗ |
| Aug 4, 2026 | Yong Yu Chief Scientific Officer | GNLX Genelux Corporation | Sale | 653 | $2.94 | $1,920 Sale | Form 4 ↗ |
| Aug 4, 2026 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 653 | $2.95 | $1,926 Sale | Form 4 ↗ |
| Aug 4, 2026 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 3,023 | $2.95 | $8,918 Sale | Form 4 ↗ |
| Jul 1, 2026 | John W. Smither Director | GNLX Genelux Corporation | Sale | 12,000 | $2.91 | $34.9K Sale | Form 4 ↗ |
| Jun 3, 2026 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 192 | $2.93 | $563 Sale | Form 4 ↗ |
| Jun 1, 2026 | John Thomas Director | GNLX Genelux Corporation | Sale | 10,000 | $2.98 | $29.8K Sale | Form 4 ↗ |
| May 11, 2026 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 605 | $2.97 | $1,797 Sale | Form 4 ↗ |
| May 11, 2026 | Yong Yu Chief Scientific Officer | GNLX Genelux Corporation | Sale | 605 | $2.97 | $1,797 Sale | Form 4 ↗ |
| May 11, 2026 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 2,798 | $2.94 | $8,226 Sale | Form 4 ↗ |
| May 11, 2026 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 270 | $2.98 | $805 Sale | Form 4 ↗ |
| Mar 25, 2026 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 240 | $2.51 | $602 Sale | Form 4 ↗ |
| Mar 24, 2026 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 345 | $2.42 | $835 Sale | Form 4 ↗ |
| Mar 24, 2026 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 906 | $2.42 | $2,193 Sale | Form 4 ↗ |
| Mar 24, 2026 | Yong Yu SVP, Clinical Development | GNLX Genelux Corporation | Sale | 906 | $2.42 | $2,193 Sale | Form 4 ↗ |
| Mar 24, 2026 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 3,582 | $2.42 | $8,668 Sale | Form 4 ↗ |
| Mar 2, 2026 | John Thomas Director | GNLX Genelux Corporation | Sale | 10,000 | $2.90 | $29.0K Sale | Form 4 ↗ |
| Dec 5, 2025 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 165 | $4.69 | $774 Sale | Form 4 ↗ |
| Dec 1, 2025 | John Thomas Director | GNLX Genelux Corporation | Sale | 10,000 | $5.00 | $50.0K Sale | Form 4 ↗ |
| Nov 17, 2025 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 4,509 | $5.37 | $24.2K Sale | Form 4 ↗ |
| Nov 17, 2025 | Yong Yu SVP, Clinical Development | GNLX Genelux Corporation | Sale | 973 | $5.37 | $5,225 Sale | Form 4 ↗ |
| Nov 17, 2025 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 973 | $5.37 | $5,225 Sale | Form 4 ↗ |
| Nov 17, 2025 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 343 | $5.37 | $1,842 Sale | Form 4 ↗ |
| Sep 3, 2025 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 580 | $3.36 | $1,949 Sale | Form 4 ↗ |
| Aug 21, 2025 | Thomas Zindrick President and CEO | GNLX Genelux Corporation | Sale | 12,673 | $3.33 | $42.2K Sale | Form 4 ↗ |
| Aug 21, 2025 | Yong Yu SVP, Clinical Development | GNLX Genelux Corporation | Sale | 3,219 | $3.36 | $10.8K Sale | Form 4 ↗ |
| Aug 21, 2025 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 1,463 | $3.36 | $4,916 Sale | Form 4 ↗ |
| Aug 21, 2025 | Joseph Cappello Chief Technical Officer | GNLX Genelux Corporation | Sale | 1,270 | $3.33 | $4,229 Sale | Form 4 ↗ |
| Aug 21, 2025 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 1,244 | $3.36 | $4,180 Sale | Form 4 ↗ |
| May 12, 2025 | Sean Ryder General Counsel | GNLX Genelux Corporation | Sale | 4,475 | $2.92 | $13.1K Sale | Form 4 ↗ |
| May 12, 2025 | Thomas Zindrick President and CEO, Director | GNLX Genelux Corporation | Sale | 10,764 | $2.92 | $31.4K Sale | Form 4 ↗ |
| May 12, 2025 | Yong Yu VP, Clinical Trial Operations | GNLX Genelux Corporation | Sale | 5,579 | $2.92 | $16.3K Sale | Form 4 ↗ |
| May 12, 2025 | Joseph Cappello VP, Pharmaceutical Development | GNLX Genelux Corporation | Sale | 4,737 | $2.92 | $13.8K Sale | Form 4 ↗ |
| May 12, 2025 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 1,259 | $2.92 | $3,676 Sale | Form 4 ↗ |
| Dec 30, 2024 | James L. Tyree Director | GNLX Genelux Corporation | Sale | 3,460 | $2.46 | $8,512 Sale | Form 4 ↗ |
| Dec 16, 2024 | Thomas Zindrick President and CEO, Director | GNLX Genelux Corporation | Sale | 14,315 | $2.34 | $33.5K Sale | Form 4 ↗ |
| Dec 16, 2024 | Lourie S. Zak Chief Financial Officer | GNLX Genelux Corporation | Sale | 2,103 | $2.34 | $4,921 Sale | Form 4 ↗ |
| Dec 16, 2024 | Ralph Smalling Head of Regulatory | GNLX Genelux Corporation | Sale | 2,510 | $2.34 | $5,873 Sale | Form 4 ↗ |
| Dec 16, 2024 | Joseph Cappello VP, Pharmaceutical Development | GNLX Genelux Corporation | Sale | 6,300 | $2.34 | $14.7K Sale | Form 4 ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 9:28 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances